InMed Pharmaceuticals Inc
INM1.230USD
-0.030-2.38%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
3.20MMarket Cap
0.03P/E TTM
More Details of InMed Pharmaceuticals Inc Company
InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
InMed Pharmaceuticals Inc Info
Ticker SymbolINM
Company nameInMed Pharmaceuticals Inc
IPO dateJun 21, 2001
CEOAdams (Eric A)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJun 21
Address1445-885 West Georgia St.
CityVANCOUVER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeV6C 3E8
Phone16046697207
Websitehttps://www.inmedpharma.com/
Ticker SymbolINM
IPO dateJun 21, 2001
CEOAdams (Eric A)
Company Executives of InMed Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Independent Director
Independent Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Mr. Eric A. Adams
Mr. Eric A. Adams
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. N. Netta (Neeta) Jagpal, CPA
Ms. N. Netta (Neeta) Jagpal, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. John Bathery
Mr. John Bathery
Director
Director
--
--
Mr. Bryan T. Baldasare
Mr. Bryan T. Baldasare
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Andrew Harold Hull
Mr. Andrew Harold Hull
Independent Chairman of the Board
Independent Chairman of the Board
1.91K
--
Dr. Eric Chih-Hsien Hsu, Ph.D.
Dr. Eric Chih-Hsien Hsu, Ph.D.
Senior Vice President - Preclinical Research and Development
Senior Vice President - Preclinical Research and Development
2.00
--
Mr. Michael Henry Woudenberg
Mr. Michael Henry Woudenberg
Chief Operating Officer
Chief Operating Officer
1.00
--
Mr. Neil A. Klompas, CPA
Mr. Neil A. Klompas, CPA
Independent Director
Independent Director
--
--
Mr. Colin Clancy
Mr. Colin Clancy
Vice President, Investor Relations and Corporate Communications
Vice President, Investor Relations and Corporate Communications
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
-100.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sabby Management, LLC
7.85%
Yorkville Advisors Global, LP.
2.87%
DRW Securities, LLC
1.28%
Virtu Americas LLC
0.73%
Renaissance Technologies LLC
0.60%
Other
86.68%
Shareholders
Shareholders
Proportion
Sabby Management, LLC
7.85%
Yorkville Advisors Global, LP.
2.87%
DRW Securities, LLC
1.28%
Virtu Americas LLC
0.73%
Renaissance Technologies LLC
0.60%
Other
86.68%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
10.71%
Investment Advisor
1.64%
Research Firm
0.74%
Hedge Fund
0.60%
Individual Investor
0.15%
Other
86.16%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
30
135.23K
4.82%
+48.77K
2025Q2
37
127.03K
6.34%
+18.71K
2025Q1
34
127.03K
10.75%
+32.44K
2024Q4
33
169.52K
14.04%
+76.54K
2024Q3
35
65.17K
63.92%
+11.73K
2024Q2
34
30.10K
7.60%
-6.51K
2024Q1
33
42.40K
13.49%
-1.13K
2023Q4
31
40.41K
15.37%
-91.29K
2023Q3
32
1.59K
1.33%
-12.58K
2023Q2
37
1.04K
0.99%
-13.60K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sabby Management, LLC
36.13K
1.52%
+20.77K
+135.22%
Dec 31, 2024
Yorkville Advisors Global, LP.
80.37K
3.37%
+80.37K
--
Dec 13, 2024
Adams (Eric Ashley)
2.20K
0.09%
-5.70K
-72.17%
Jun 30, 2025
Hull (Andrew Harold)
1.91K
0.08%
-425.00
-18.19%
Jun 30, 2025
SBI Securities Co., Ltd.
300.00
0.01%
--
--
Jun 30, 2025
Banque Cantonale Vaudoise
6.00
0%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Pure Cannabis ETF
0%
AdvisorShares Pure Cannabis ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Date
Type
Ratio
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Nov 12, 2024
Merger
20→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
Aug 26, 2022
Merger
25→1
FAQs
Who are the top five shareholders of InMed Pharmaceuticals Inc?
The top five shareholders of InMed Pharmaceuticals Inc are:
Sabby Management, LLC holds 36.13K shares, accounting for 1.52% of the total shares.
Yorkville Advisors Global, LP. holds 80.37K shares, accounting for 3.37% of the total shares.
Adams (Eric Ashley) holds 2.20K shares, accounting for 0.09% of the total shares.
Hull (Andrew Harold) holds 1.91K shares, accounting for 0.08% of the total shares.
SBI Securities Co., Ltd. holds 300.00 shares, accounting for 0.01% of the total shares.
Sabby Management, LLC holds 36.13K shares, accounting for 1.52% of the total shares.
Yorkville Advisors Global, LP. holds 80.37K shares, accounting for 3.37% of the total shares.
Adams (Eric Ashley) holds 2.20K shares, accounting for 0.09% of the total shares.
Hull (Andrew Harold) holds 1.91K shares, accounting for 0.08% of the total shares.
SBI Securities Co., Ltd. holds 300.00 shares, accounting for 0.01% of the total shares.
What are the top three shareholder types of InMed Pharmaceuticals Inc?
The top three shareholder types of InMed Pharmaceuticals Inc are:
Sabby Management, LLC
Yorkville Advisors Global, LP.
DRW Securities, LLC
Sabby Management, LLC
Yorkville Advisors Global, LP.
DRW Securities, LLC
How many institutions hold shares of InMed Pharmaceuticals Inc (INM)?
As of 2025Q3, 30 institutions hold shares of InMed Pharmaceuticals Inc, with a combined market value of approximately 135.23K, accounting for 4.82% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.52%.
What is the biggest source of revenue for InMed Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for InMed Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
